{"analyses":[{"ciLowerLimit":"-7.499","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.704","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"2.603","estimateComment":"The treatment was considered efficacious if the group by time interaction for LVEDV was statistically significant at a two-sided p\\<0.05 and the expected LVEDV was lower for carvedilol than placebo over time.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.36","paramType":"Slope","paramValue":"-2.397","statisticalComment":"The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.","statisticalMethod":"Generalized Estimating Equation (GEE)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.0157","value":"99.7507"},{"groupId":"OG001","spread":"3.0337","value":"93.3155"}]}],"title":"BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.9788","value":"99.3216"},{"groupId":"OG001","spread":"3.2631","value":"95.7434"}]}],"title":"6m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.975","value":"102.378"},{"groupId":"OG001","spread":"3.3889","value":"96.5002"}]}],"title":"12m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.5977","value":"101.174"},{"groupId":"OG001","spread":"4.0815","value":"99.4656"}]}],"title":"18m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.0356","value":"100.659"},{"groupId":"OG001","spread":"4.6469","value":"98.9602"}]}],"title":"24m"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"The amount of blood (in ml) in the heart's left ventricle just before the heart contracts. The mean is reported by arm at each timepoint with corresponding standard errors.","dispersionType":"Standard Error","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation","title":"Average Left Ventricular End-diastolic Volume","type":"SECONDARY","unitOfMeasure":"ml"}